Analyst Consensus ?
ConsensusBuy24 ratings
Bullish1770.8%
Neutral729.2%
Bearish00.0%
SS&C Technologies Holdings, Inc. · SSNC · FY2026 Q2 · Calendar Q3 2026
SS&C Q2: Renewals, AI and digital investment lift outlook
SS&C's raised outlook is supported by renewal-driven organic growth, AI-enabled services and expanding digital-investment and healthcare platforms. The evidence is constructive, but the thesis depends on sustaining growth after large renewals and managing investment, regulatory and leverage risks.
Reported After market closeNASDAQTechnology
$21.01B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$1.76
Consensus $1.68
EPS surprise
+4.8%
Reported versus consensus
Reported revenue
$1.70B
Consensus $1.66B
Revenue surprise
+2.0%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
+10.4%
Event window
SPY move
+0.1%
Same window
Abnormal move
+10.2%
Stock minus SPY
Volume
1.9×
Versus trailing sessions
Subsequent drift
+12.3%
Up to 20 sessions
SSNCSPY benchmark
Ask FN2 about SSNC FY2026 Q2
Transcript, numbers and history already loaded
Why did SSNC rise 10.4% after beating EPS estimates in FY2026 Q2?What changed in SSNC's guidance and outlook in FY2026 Q2?Give me the bull and bear case for SSNC after FY2026 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, management continued to emphasize AI-enabled automation and acquisitions while adding more detail on tokenized investment infrastructure, regulated digital cash and the DomaniRx Medicare GLP-1 Bridge Program. The current analysis also identifies a raised full-year outlook and a larger emphasis on refinancing and capital structure.
Guidance delta
Management raised the full-year outlook, targeting mid-teens revenue growth and 5.5% organic growth.
Key takeaways
- Management described record Q2 performance, with growth supported by large multiyear license renewals, AI-enabled services and acquisitions.
- The company is expanding tokenized investment capabilities and regulated digital-cash settlement solutions.
- DomaniRx's Medicare GLP-1 Bridge Program processed nearly 3 million claims, adding a healthcare-platform growth initiative.
- Capital allocation emphasized share repurchases while maintaining selective investment in R&D, AI and cybersecurity.
- The central question is whether renewal-driven momentum and newer platforms can sustain organic growth.
Management priorities
- Scale tokenized investment capabilities and stablecoin settlement solutions.
- Roll out Genesis, Eclipse, DBC and enhanced WorkHQ AI guardrails.
- Continue selective acquisitions and integration, including EMEA expansion.
- Refinance 2027 bonds to optimize the capital structure.
- Balance share repurchases with investment in R&D, AI and cybersecurity.
Follow SSNC with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$89.54Current
$65Low
$89.6Average
$115High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 23, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| DA Davidson | Buy | Buy | Maintain | Oct 22, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 31, 2026 |
| Needham | Buy | Buy | Maintain | Jul 24, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Jul 20, 2026 |
| Jefferies | Buy | Buy | Maintain | Jul 20, 2026 |
| UBS | Buy | Buy | Maintain | Apr 24, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Apr 24, 2026 |
| Raymond James | Strong Buy | Strong Buy | Maintain | Oct 24, 2025 |
| Citigroup | Buy | Buy | Maintain | Feb 15, 2024 |
| Truist Securities | Hold | Hold | Maintain | Feb 14, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | Jul 28, 2023 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 6, 2022 |
| Rosenblatt | Buy | Buy | Maintain | Jul 29, 2020 |
| BTIG | Buy | Buy | Maintain | Jan 13, 2020 |
| Wells Fargo | Buy | Buy | Maintain | Nov 5, 2019 |
| Buckingham Research | Buy | Buy | Maintain | Jul 30, 2019 |
| Buckingham | Buy | Buy | Maintain | Jan 25, 2019 |
| Deutsche Bank | Buy | Hold | Upgrade | Sep 10, 2018 |
| William Blair | Perform | Outperform | Downgrade | Jan 19, 2018 |
| Macquarie | Outperform | Neutral | Upgrade | Feb 16, 2017 |
| Avondale Partners | Market Perform | Market Perform | Maintain | Jan 6, 2016 |
| Evercore ISI Group | Buy | Buy | Maintain | Oct 6, 2015 |
| Sandler O'Neill | Hold | Hold | Maintain | Jun 26, 2015 |
| Sidoti & Co. | Neutral | Buy | Downgrade | Mar 16, 2015 |
Named analyst price targets
Upside is calculated against the persisted current price $89.54. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| D.A. Davidson | Analyst unavailable | $104 | $87.09 | +16.1% | Oct 21, 2026 |
| Jefferies | Analyst unavailable | $100 | $86.92 | +11.7% | Oct 21, 2026 |
| UBS | Kevin McVeigh | $101 | $79.29 | +12.8% | Sep 9, 2026 |
| RBC Capital | Analyst unavailable | $101 | $83.42 | +12.8% | Aug 31, 2026 |
| UBS | Kevin McVeigh | $99 | $80.28 | +10.6% | Aug 13, 2026 |
| RBC Capital | Analyst unavailable | $92 | $74.34 | +2.7% | Jul 24, 2026 |
| Jefferies | Analyst unavailable | $83 | $69.56 | -7.3% | Jul 20, 2026 |
| UBS | Analyst unavailable | $115 | $66.09 | +28.4% | Apr 24, 2026 |
| Morgan Stanley | James Faucette | $78 | $66.76 | -12.9% | Apr 24, 2026 |
| Needham | Analyst unavailable | $90 | $70.06 | +0.5% | Apr 24, 2026 |
| Jefferies | Analyst unavailable | $92 | $71.3 | +2.7% | Apr 21, 2026 |
| D.A. Davidson | Peter Heckmann | $96 | $72.39 | +7.2% | Apr 17, 2026 |
| Morgan Stanley | James Faucette | $86 | $76.38 | -4.0% | Feb 9, 2026 |
| Needham | Mayank Tandon | $95 | $74.98 | +6.1% | Feb 6, 2026 |
| D.A. Davidson | Analyst unavailable | $106 | $85.62 | +18.4% | Jan 22, 2026 |
| Jefferies | Analyst unavailable | $105 | $85.39 | +17.3% | Oct 28, 2025 |
| RBC Capital | Analyst unavailable | $99 | $84.61 | +10.6% | Oct 24, 2025 |
| D.A. Davidson | Peter Heckmann | $102 | $84.21 | +13.9% | Oct 24, 2025 |
| UBS | Kevin McVeigh | $112 | $80.88 | +25.1% | Oct 24, 2025 |
| Raymond James | Patrick O'Shaughnessy | $105 | $84.21 | +17.3% | Oct 24, 2025 |
| Needham | Analyst unavailable | $105 | $80.88 | +17.3% | Oct 24, 2025 |
| Raymond James | Patrick O'Shaughnessy | $101 | $79.54 | +12.8% | Oct 17, 2025 |
| UBS | Kevin McVeigh | $110 | $90.2 | +22.9% | Aug 22, 2025 |
| UBS | Kevin McVeigh | $105 | $83.08 | +17.3% | Jul 22, 2025 |
| D.A. Davidson | Peter Heckmann | $92 | $76.46 | +2.7% | Sep 19, 2024 |
| RBC Capital | Daniel Perlin | $75 | $72.44 | -16.2% | Jul 26, 2024 |
| D.A. Davidson | Peter Heckmann | $84 | $68.44 | -6.2% | Jul 18, 2024 |
| Raymond James | Analyst unavailable | $74 | $63.66 | -17.4% | Feb 8, 2023 |
| Needham | Analyst unavailable | $76 | $61.64 | -15.1% | Feb 8, 2023 |
| RBC Capital | Analyst unavailable | $77 | $57.65 | -14.0% | Jul 28, 2022 |
| Morgan Stanley | Analyst unavailable | $65 | $57.96 | -27.4% | Jul 28, 2022 |
| Raymond James | Analyst unavailable | $83 | $57.89 | -7.3% | Jul 28, 2022 |
| UBS | Analyst unavailable | $77 | $57.72 | -14.0% | Jul 28, 2022 |
| Credit Suisse | Analyst unavailable | $78 | $58.25 | -12.9% | Jul 28, 2022 |
| Needham | Analyst unavailable | $75 | $61.53 | -16.2% | Jul 28, 2022 |
| Piper Sandler | Analyst unavailable | $67 | $59.24 | -25.2% | Jul 6, 2022 |
| RBC Capital | Analyst unavailable | $81 | $66.27 | -9.5% | Apr 29, 2022 |
| Needham | Analyst unavailable | $92 | $69.04 | +2.7% | Apr 29, 2022 |
Track every rating change on SSNC the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationSS&C Technologies Holdings, Inc. offers a diverse portfolio of software solutions and related services, catering primarily to the financial services and healthcare industries. The company's sophisticated technology infrastructure spans various critical functions within finance, including securities accounting; front-office capabilities such as trading and financial modeling; middle-office tasks like portfolio oversight and reporting; and comprehensive back-office operations encompassing general accounting, performance measurement, data reconciliation, processing, clearing, regulatory compliance, and tax reporting. In the healthcare sector, SS&C provides specialized solutions for claims adjudication, benefits administration, care management, and business intelligence. These offerings are instrumental in helping professionals in both domains automate intricate business processes and efficiently handle their extensive information processing demands.…
Historical context
All SSNC earningsTechnology peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| WDC Western Digital Corporation | FY2027 Q1 · Calendar Q4 2026 | +12.9% | -6.4% | Western Digital pairs strong FY27 Q1 growth with an accelerated HDD roadmap |
| ROP Roper Technologies, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +9.7% | Roper raises DEPS outlook as AI adoption expands across portfolio |
| VRSN VeriSign, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -0.9% | VeriSign sustains domain growth as .web and security launches near |
| TTMI TTM Technologies, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -27.2% | TTM Technologies: Record Q3, but execution risks remain |
| NOK Nokia Oyj | FY2026 Q3 · Calendar Q4 2026 | — | -12.4% | Nokia Q3: AI and Cloud Growth Lift Margins, Cash Flow Lags |
| CACI CACI International Inc | FY2027 Q1 · Calendar Q4 2026 | +16.6% | -1.5% | CACI raises FY27 outlook as backlog and defense awards expand |
Latest beats and misses
Who reports nextBeat on EPS
- NDAQFY2026 Q3 · October 22, 2026+2.0% EPS+7.5% move
- DOWFY2026 Q3 · October 22, 2026+11.3% EPS+4.7% move
- ALLEFY2026 Q3 · October 22, 2026+4.0% EPS+11.0% move
- CBREFY2026 Q3 · October 22, 2026+4.6% EPS-2.5% move
- RFY2026 Q3 · October 22, 2026+4.3% EPS+10.5% move
- WDCFY2027 Q1 · October 22, 2026+12.9% EPS-6.4% move
Missed on EPS
Get the SSNC recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-07-24T14:04:20.348055+00:00
- FN2 earnings calendar · 2026-08-27T01:23:13.912278+00:00
- Polygon adjusted daily market bars · 2026-10-23T02:30:42.121911+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-23T02:30:42.119142+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-23. For educational purposes only; not investment advice.